HRP20140745T1 - Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja - Google Patents
Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja Download PDFInfo
- Publication number
- HRP20140745T1 HRP20140745T1 HRP20140745AT HRP20140745T HRP20140745T1 HR P20140745 T1 HRP20140745 T1 HR P20140745T1 HR P20140745A T HRP20140745A T HR P20140745AT HR P20140745 T HRP20140745 T HR P20140745T HR P20140745 T1 HRP20140745 T1 HR P20140745T1
- Authority
- HR
- Croatia
- Prior art keywords
- amisulpride
- use according
- vomiting
- induced nausea
- single dose
- Prior art date
Links
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 title claims 14
- 229960003036 amisulpride Drugs 0.000 title claims 14
- 206010047700 Vomiting Diseases 0.000 title claims 2
- 238000002512 chemotherapy Methods 0.000 title claims 2
- 230000003474 anti-emetic effect Effects 0.000 claims 2
- 239000002111 antiemetic agent Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229940127240 opiate Drugs 0.000 claims 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Amisulprid za uporabu u liječenju stanja koje je mučnina i povraćanje izazvano kemoterapijom.
2. Amisulprid za uporabu prema zahtjevu 1, gdje liječeni bolesnik također dobiva i opijat.
3. Amisulprid za uporabu prema zahtjevu 2 gdje je taj opijat morfij.
4. Amisulprid za uporabu prema bilo kojem od prethodnih zahtjeva, za primjenu intravenskom, intramuskularnom ili subkutanom injekcijom.
5. Amisulprid za uporabu prema bilo kojem od prethodnih zahtjeva, gdje je liječeni bolesnik čovjek.
6. Amisulprid za uporabu prema bilo kojem od prethodnih zahtjeva, u obliku pojedinačne doze koja sadrži manje od 50 mg amisulprida.
7. Amisulprid za uporabu prema zahtjevu 6, gdje pojedinačna doza sadrži 1 do 35 mg amisulprida.
8. Amisulprid za uporabu prema zahtjevu 7, gdje se pojedinačna doza od 1 do 35 mg daje jednom ili dva puta na dan ljudskom bolesniku.
9. Amisulprid za uporabu prema bilo kojem od prethodnih zahtjeva, za uporabu u kombinaciji s drugim antiemetikom.
10. Amisulprid za uporabu prema zahtjevu 9, gdje je taj drugi antiemetik 5HT3 antagonist.
11. Amisulprid za uporabu prema zahtjevu 10, gdje je 5HT3 antagonist ondansetron.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1004020.2A GB201004020D0 (en) | 2010-03-11 | 2010-03-11 | New therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140745T1 true HRP20140745T1 (hr) | 2014-09-26 |
Family
ID=42136792
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140744AT HRP20140744T1 (hr) | 2010-03-11 | 2014-08-01 | Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja |
| HRP20140745AT HRP20140745T1 (hr) | 2010-03-11 | 2014-08-01 | Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja |
| HRP20180436TT HRP20180436T1 (hr) | 2010-03-11 | 2018-03-14 | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140744AT HRP20140744T1 (hr) | 2010-03-11 | 2014-08-01 | Uporaba amisulprida za lijeäśenje post-operativne muäśnine i povraä†anja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180436TT HRP20180436T1 (hr) | 2010-03-11 | 2018-03-14 | Upotreba amisulprida u liječenju mučnine i povraćanja uzrokovanih opijatima |
Country Status (27)
| Country | Link |
|---|---|
| US (11) | US9084765B2 (hr) |
| EP (3) | EP2567690B1 (hr) |
| JP (2) | JP5886213B2 (hr) |
| KR (1) | KR101738201B1 (hr) |
| CN (1) | CN102892407B (hr) |
| AU (1) | AU2011225898B2 (hr) |
| BR (1) | BR112012022746B1 (hr) |
| CA (1) | CA2792392C (hr) |
| CY (3) | CY1115487T1 (hr) |
| DK (3) | DK2567690T3 (hr) |
| EA (1) | EA030335B1 (hr) |
| ES (3) | ES2496092T3 (hr) |
| GB (1) | GB201004020D0 (hr) |
| HK (1) | HK1179152A1 (hr) |
| HR (3) | HRP20140744T1 (hr) |
| HU (1) | HUE037088T2 (hr) |
| IL (1) | IL221746A (hr) |
| LT (1) | LT2796171T (hr) |
| MX (3) | MX370629B (hr) |
| NO (1) | NO2796171T3 (hr) |
| NZ (1) | NZ602279A (hr) |
| PL (3) | PL2796171T3 (hr) |
| PT (3) | PT2796171T (hr) |
| RS (3) | RS53466B (hr) |
| SI (3) | SI2567690T1 (hr) |
| SM (2) | SMT201400127B (hr) |
| WO (1) | WO2011110854A2 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| CN104435861A (zh) * | 2014-12-22 | 2015-03-25 | 济南伟传信息技术有限公司 | 一种治疗妊娠剧吐的茶 |
| GB201506116D0 (en) * | 2015-04-10 | 2015-05-27 | Acacia Pharma Ltd | Kit and combination therapy for nausea and vomiting |
| JP2018530744A (ja) | 2015-09-02 | 2018-10-18 | カリフォルニア インスティチュート オブ テクノロジー | 低濃度の硫化水素ガスの分光学的検出のための方法および装置 |
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| BR112020011189A2 (pt) | 2017-12-05 | 2020-11-17 | Sunovion Pharmaceuticals Inc. | misturas não racêmicas e usos das mesmas |
| CA3088356A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| WO2020247603A1 (en) * | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| AU2020286441A1 (en) * | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| EP4175631A1 (en) * | 2020-07-06 | 2023-05-10 | Acacia Pharma Ltd | Therapy of post-operative nausea and vomiting |
| WO2023179542A1 (en) | 2022-03-21 | 2023-09-28 | Gasherbrum Bio , Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| WO2023198140A1 (en) | 2022-04-14 | 2023-10-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024125602A1 (en) | 2022-12-15 | 2024-06-20 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2024138048A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024131869A1 (en) | 2022-12-22 | 2024-06-27 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2415099A1 (fr) * | 1978-01-20 | 1979-08-17 | Ile De France | Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes |
| US6169094B1 (en) * | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
| DE10163421A1 (de) * | 2001-12-21 | 2003-07-31 | Gruenenthal Gmbh | Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum |
| DE102005013726A1 (de) * | 2005-03-22 | 2006-09-28 | Grünenthal GmbH | Transdermale therapeutische Systeme mit verbesserter Verträglichkeit |
| GB0506800D0 (en) * | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| WO2007067714A2 (en) * | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| CA2640460C (en) * | 2006-01-27 | 2015-05-26 | Eurand, Inc | Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids |
| WO2007096489A1 (fr) * | 2006-02-17 | 2007-08-30 | Trimaran Limited | Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions |
| US7825156B2 (en) * | 2007-02-02 | 2010-11-02 | Copharms | Method of treating bipolar depression with a benzamide derivative |
| EP3090743A1 (en) * | 2008-01-09 | 2016-11-09 | Charleston Laboratories, Inc. | Pharmaceutical compositions for treating headache and eliminating nausea |
| US8138169B2 (en) * | 2008-04-11 | 2012-03-20 | Comgenrx, Inc. | Combination therapy for bipolar disorder |
| GB201004020D0 (en) | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
-
2010
- 2010-03-11 GB GBGB1004020.2A patent/GB201004020D0/en not_active Ceased
-
2011
- 2011-03-10 DK DK12188047.0T patent/DK2567690T3/da active
- 2011-03-10 PL PL14173186T patent/PL2796171T3/pl unknown
- 2011-03-10 SI SI201130237T patent/SI2567690T1/sl unknown
- 2011-03-10 HU HUE14173186A patent/HUE037088T2/hu unknown
- 2011-03-10 EA EA201290833A patent/EA030335B1/ru unknown
- 2011-03-10 EP EP12188047.0A patent/EP2567690B1/en active Active
- 2011-03-10 AU AU2011225898A patent/AU2011225898B2/en active Active
- 2011-03-10 RS RS20140410A patent/RS53466B/en unknown
- 2011-03-10 MX MX2015003664A patent/MX370629B/es unknown
- 2011-03-10 ES ES11709793.1T patent/ES2496092T3/es active Active
- 2011-03-10 DK DK11709793.1T patent/DK2544657T3/da active
- 2011-03-10 BR BR112012022746-7A patent/BR112012022746B1/pt active IP Right Grant
- 2011-03-10 SI SI201130236T patent/SI2544657T1/sl unknown
- 2011-03-10 PL PL11709793T patent/PL2544657T3/pl unknown
- 2011-03-10 EP EP14173186.9A patent/EP2796171B1/en active Active
- 2011-03-10 PL PL12188047T patent/PL2567690T3/pl unknown
- 2011-03-10 MX MX2012010411A patent/MX2012010411A/es active IP Right Grant
- 2011-03-10 PT PT141731869T patent/PT2796171T/pt unknown
- 2011-03-10 LT LTEP14173186.9T patent/LT2796171T/lt unknown
- 2011-03-10 NZ NZ602279A patent/NZ602279A/en unknown
- 2011-03-10 DK DK14173186.9T patent/DK2796171T3/en active
- 2011-03-10 WO PCT/GB2011/050472 patent/WO2011110854A2/en active Application Filing
- 2011-03-10 CN CN201180018552.XA patent/CN102892407B/zh not_active Ceased
- 2011-03-10 EP EP11709793.1A patent/EP2544657B1/en active Active
- 2011-03-10 PT PT121880470T patent/PT2567690E/pt unknown
- 2011-03-10 NO NO14173186A patent/NO2796171T3/no unknown
- 2011-03-10 PT PT117097931T patent/PT2544657E/pt unknown
- 2011-03-10 CA CA2792392A patent/CA2792392C/en active Active
- 2011-03-10 KR KR1020127024111A patent/KR101738201B1/ko active IP Right Grant
- 2011-03-10 JP JP2012556586A patent/JP5886213B2/ja active Active
- 2011-03-10 RS RS20180349A patent/RS57032B1/sr unknown
- 2011-03-10 ES ES14173186.9T patent/ES2665418T3/es active Active
- 2011-03-10 RS RS20140411A patent/RS53467B/en unknown
- 2011-03-10 SI SI201131446T patent/SI2796171T1/en unknown
- 2011-03-10 ES ES12188047.0T patent/ES2496099T3/es active Active
-
2012
- 2012-07-26 US US13/559,168 patent/US9084765B2/en active Active
- 2012-07-26 US US13/559,253 patent/US8686019B2/en active Active
- 2012-09-02 IL IL221746A patent/IL221746A/en active IP Right Grant
- 2012-09-07 MX MX2019015396A patent/MX2019015396A/es unknown
-
2013
- 2013-05-22 HK HK13106057.2A patent/HK1179152A1/zh unknown
-
2014
- 2014-02-04 US US14/172,194 patent/US9119836B2/en active Active
- 2014-08-01 HR HRP20140744AT patent/HRP20140744T1/hr unknown
- 2014-08-01 HR HRP20140745AT patent/HRP20140745T1/hr unknown
- 2014-08-14 CY CY20141100657T patent/CY1115487T1/el unknown
- 2014-08-14 CY CY20141100656T patent/CY1115485T1/el unknown
- 2014-09-10 SM SM201400127T patent/SMT201400127B/xx unknown
- 2014-09-10 SM SM201400126T patent/SMT201400126B/xx unknown
-
2015
- 2015-07-29 US US14/812,148 patent/US9545426B2/en active Active
- 2015-09-24 JP JP2015187057A patent/JP6279526B2/ja active Active
-
2016
- 2016-12-09 US US15/374,174 patent/US9889118B2/en active Active
-
2017
- 2017-10-23 US US15/790,481 patent/US10085970B2/en active Active
-
2018
- 2018-03-14 HR HRP20180436TT patent/HRP20180436T1/hr unknown
- 2018-04-18 CY CY20181100416T patent/CY1120170T1/el unknown
- 2018-08-20 US US16/105,268 patent/US10525033B2/en active Active
-
2019
- 2019-11-27 US US16/697,986 patent/US20200093792A1/en not_active Abandoned
-
2020
- 2020-09-08 US US17/013,987 patent/US20210228543A1/en not_active Abandoned
-
2022
- 2022-06-07 US US17/834,000 patent/US20220296570A1/en not_active Abandoned
-
2023
- 2023-01-11 US US18/095,612 patent/US20230144973A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140745T1 (hr) | Uporaba amisulprida za lijeäśenje kemoterapijom izazvane muäśnine i povraä†anja | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ587297A (en) | Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| NZ586221A (en) | Dosing regimen associated with long acting injectable paliperidone esters | |
| WO2012145752A8 (en) | Wearable automatic injection device for controlled administration of therapeutic agents | |
| GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
| MX2012012221A (es) | Dispositivo de inyeccionautomatica ponible para entrega controlada de agentes terapeuticos. | |
| NZ625440A (en) | Anti-cxcr1 compositions and methods | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| NZ576424A (en) | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor | |
| RU2015135843A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
| TW200628182A (en) | Injection device for administering a medication liquid | |
| NZ601559A (en) | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies | |
| NZ597339A (en) | Continuous administration of cilengitide in cancer treatments | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| TW201129361A (en) | Methods for treating pain | |
| MY174442A (en) | Treating critically ill patients with intravenous ibuprofen | |
| NZ592114A (en) | Composition comprising sortase anchored surface proteins of streptococcus uberis | |
| ATE529127T1 (de) | Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung | |
| RU2007120403A (ru) | Способ локальной терапии аутоиммунного артрита | |
| MX2010010372A (es) | Uso de la composicion morfina-metamizol como medicamento para el tratamiento del dolor neuropatico. | |
| UA54839U (ru) | Способ лечения псориаза | |
| RU2010126053A (ru) | Применение аналогов соматостатина при менингиоме | |
| WO2008055092A3 (en) | Use of enoxaparin sodium for treating patients with acute ischemic stroke |